Compare Amazon.com Inc (AMZN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Amazon (AMZN) trades at $245.34, down 0.69% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings, beating expectations with EPS of $2.78, and shows robust revenue growth, reaching $716.92B in 2025. Operating cash flow remains strong at $139.51B, though heavy investing activities result in modest net cash flow. Analyst sentiment is overwhelmingly positive, with 88.3% recommending Buy and a consensus price target of $320.75.

The outlook for Amazon is favorable, driven by AI advancements in AWS and expanding market penetration. Key risks include intense competition in retail and cloud sectors, high capital expenditures, and macroeconomic pressures. Investors should weigh the strong growth trajectory against these risks, with the stock offering significant upside based on analyst targets.

Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.

Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.